XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 52.59

Change

-0.04 (-0.08)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.18 (+0.69%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.41 (+0.82%)

USD 113.22B
SXR8:F iShares Core S&P 500 UCITS ETF..

+3.22 (+0.63%)

USD 83.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.44 (+0.82%)

USD 77.76B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.16 (+0.75%)

USD 73.13B
EUNL:F iShares Core MSCI World UCITS ..

+0.49 (+0.53%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

+2.10 (+0.93%)

USD 56.29B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.11 (+0.75%)

USD 54.81B
VUAA:F Vanguard S&P 500 UCITS Acc

+1.04 (+1.14%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.91 (+1.00%)

USD 51.63B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.79% 56% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.79% 54% F 56% F
Trailing 12 Months  
Capital Gain 7.41% 52% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.41% 50% F 54% F
Trailing 5 Years  
Capital Gain 67.22% 87% B+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.22% 86% B+ 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 10.85% 85% B 78% C+
Dividend Return 10.85% 84% B 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.75% 57% F 79% B-
Risk Adjusted Return 100.90% 99% N/A 97% N/A
Market Capitalization 0.85B 71% C- 56% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike